ProShares Ultra NASDAQ Biotechnology
25 hedge funds and large institutions have $7.83M invested in ProShares Ultra NASDAQ Biotechnology in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
130% more capital invested
Capital invested by funds: $3.4M → $7.83M (+$4.43M)
47% more call options, than puts
Call options by funds: $2.14M | Put options by funds: $1.46M
32% more funds holding
Funds holding: 19 → 25 (+6)
3.29% more ownership
Funds ownership: 3.85% → 7.14% (+3.3%)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$809K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$691K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$653K |
| 4 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
+$532K |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
+$324K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.5M |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$72K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$17.2K |
| 4 |
Morgan Stanley
New York
|
-$14K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$12.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Simplex Trading
Chicago,
Illinois
| – | -$72K | -1,514 | Closed |
|
BIB Hedge Fund Activity: Q4 2022 in Review
25 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q4 2022, worth a combined $7.83M — up 130% from $3.4M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BIB positions and 2 closed out — a net gain of 6 holders — while 3 added to existing stakes and 7 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $809K. The largest seller was Susquehanna International Group, cutting an estimated $1.5M.
- 25 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q4 2022, up from 19 in Q3 2022.
- Funds reported $7.83M of ProShares Ultra NASDAQ Biotechnology stock for Q4 2022, up 130% quarter-over-quarter.
- 8 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q4 2022 and 2 closed out, a net change of +6 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q4 2022 was Jane Street, an estimated $809K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q4 2022 was Susquehanna International Group, an estimated $1.5M sold.
Based on aggregated 13F filings for Q4 2022.